Aller au contenu

Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results From a Proof-of-Concept, Phase Ib Study

Nom du journal : Clin Cancer Res

Année : 2021

Volume : 28

Page de départ : 1087

Page de fin : 1097

Auteurs: Bauer S, Italiano A, Blay JY, Abdul Razak AR, Suarez C, Lin CC, Quek R, Hütter-Krönke ML, Cubedo R, Ferretti S, Guerreiro N, Jullion A, Orlando EJ, Clementi G, Sand DJ, Halilovic E, Fabre C,